

Division of Signal Tranduction Therapy

Standard Operating Procedure

Preparation of active CLK3 [1 - 490]

<u>Enzyme description:-</u>	CLK3 [1 - 490]
<u>Clone number:-</u>	DU 58727
<u>Source:-</u>	Recombinant
<u>Expression system:-</u>	Baculovirus expression vector system
<u>Tag:-</u>	N-terminal GST
<u>Purification method:-</u>	GSH Sepharose

Calculated molecular mass:-

Monoisotopic 85, 358.01 daltons
Average Mass 85, 412.56 daltons
[cysteines reduced, methionines have not been oxidised

Theoretical pI:- 9.12

Purity:- >80 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 mM EGTA,
10 mM DTT, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

Storage temperature:- -70 °C

Assay Buffer:-

50 mM Tris-HCl pH 7.5, 0.1mM EGTA, 10 mM DTT, 10 mM MgAc

Substrate:-

RNRYRDVSPFDHSR Final concentration: 300 uM

Division of Signal Tranduction Therapy

Clone Data Sheet

CLK3 [1 - 490]

<u>Protein</u>	CLK3 [1 - 490]
<u>Clone number</u>	DU 58727
<u>Species</u>	Human
<u>Accession number</u>	NM_003992.4
<u>Tags</u>	N-terminal GST
<u>Baculovirus expressed protein</u>	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNK KFELGLEFPNLPPYYIDGDVKLTQSMAIIRYIADKHNLGGCPKE RAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKM FEDRLCHKTYLNGDHVTPDFMLYDALDVVLYMDPMCLDAFPKL VCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSD LEVLFQGPLGSMMHCKRYRSPEPDYPLSYRWKRRRSYSREHEGR LRYPSRREPPPRRSRSRSHDRLPYQRRYRERRSDTYRCEERSP SFGEDYYGPSRSRHRRSRERGPYRTRKHAHHCHKRRTRSCSSA SSRSQQSSKRSSRSVEDDKEGHLVCRIGDWLQERYEIVGNLGE TFGKVVECLDHARGKSQVALKIIRNVGKYREAARLEINVKKIK EKDKENKFLCVLMSDWFNFHGHMCIAFELLGKNTFEFLKENNFO PYPLPHVRHMAYQLCHALRFLHENQLTHTDLKPENILFVNSEFE TLYNEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYR PPEVILELGWAQPCDVWSIGCILFEYYRGFTLFQTHENREHLM MEKILGPIPSHMIHRTRKQKYFYKGGLVWDENSDDGRYVKENCK PLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFA GLTPEERSFHTSRNPSR
<u>Native sequence</u>	Amino acids M1 – R490 (end residue) of human CLK3. Residue M232 of the fusion protein is equivalent to M1 of the native enzyme. The GST tag is located at residues 1 - 220.
<u>Protease cleavage</u>	PreScission (LEVLFQGP) residues 221 - 228
<u>Cloning sites</u>	<i>Bam</i> H1 and <i>Not</i> 1 sites of pFastBac Dual.

Division of Signal Tranduction Therapy

<u>Nucleotide sequence of insert</u>	ggatccATGCATCACTGTAAGCGATACCGCTCCCTGAACCAGAC CCGTACCTGAGCTACCGATGGAAGAGGAGGAGGTCTACAGTCGG GAACATGAAGGGAGACTGCGATACCGTCCCGAAGGGAGCCTCCC CCACGAAGATCTCGGTCCAGAACGCATGACCGCCTGCCCTACCAAG AGGAGGTACCGGGAGCGCCGTGACAGCGATAACATACCGGTGTGAA GAGCGGAGCCCATCCTTGGAGAGGACTACTATGGACCTTCACGT TCTCGTCATCGTCGGCGATCGCGGGAGAGGGGGCATACCGGACC CGCAAGCATGCCAACCACTGCCACAAACGCCGCACCAGGTCTGT AGCAGCGCCTCCTCGAGAACGCAACAGAGCAGTAAGCGCAGCAGC CGGAGTGTGGAAGATGACAAGGAGGGTCACCTGGTGTGCCGGATC GGCGATTGGCTCCAAGAGCGATATGAGATTGTGGGAAACCTGGGT GAAGGCACCTTGGCAAGGTGGAGTGCTGGACCATGCCAGA GGGAAGTCTCAGGTTGCCCTGAAGATCATCCGCAACGTGGCAAG TACCGGGAGGCTGCCGGTAGAAATCAACGTGCTAAAAAAATC AAGGAGAAGGACAAAGAAAACAAGTTCTGTGTCTTGATGTCT GAUTGGTTCAACTTCCACGGTCACATGTGCATGCCCTTGAGCTC CTGGGCAAGAACACCTTGAGTTCTGAAGGAGAATAACTCCAG CCTTACCCCTACCACATGTCCGGCACATGCCCTACCAGCTCTGC CACGCCCTTAGATTCTGCATGAGAATCAGCTGACCACATACAGAC TTGAAACCAGAGAACATCCTGTTGTGAATTCTGAGTTGAAACC CTCTACAATGAGCACAAGAGCTGTGAGGAGAAGTCAGTGAAGAAC ACCAGCATCCGAGTGGCTGACTTGGCAGTGCCACATTGACCACAT GAGCACCACACCACATTGTGGCCACCGTCACTATGCCCGCCT GAGGTGATCCTTGAGCTGGCTGGCACAGCCCTGTGACGTCTGG AGCATTGGCTGCATTCTCTTGAGTACTACCGGGCTCACACTC TTCCAGACCCACGAAAACCGAGAGCACCTGGTGTGATGGAGAAG ATCCTAGGGCCCATCCCACATGATCCACCGTACCGAGGAAG CAGAAATATTCTACAAAGGGGCCTAGTTGGGATGAGAACAGC TCTGACGGCCGGTATGTGAAGGAGAACTGCAAACCTCTGAAGAGT TACATGCTCCAAGACTCCCTGGAGCACGTGCAGCTGTTGACCTG ATGAGGAGGATGTTAGAATTGACCCCTGCCAGCGCATCACACTG GCCGAGGCCCTGCTGCACCCCTTCTTGCTGGCCTGACCCCTGAG GAGCGGTCTTCCACACCAGCCGAAACCAAGCAGAtgagcggcc gc
--------------------------------------	---